SUPPLEMENTARY INFORMATION: In the **Federal Register** of February 17, 1995 (60 FR 9554), FDA issued a proposed rule to include additional labeling (warning and directions) for all topically-applied acne treatment drug products containing benzoyl peroxide. Interested persons were given until May 18, 1995, to submit written comments on the proposal.

In response to the proposal, the Nonprescription Drug Manufacturers Association (NDMA) requested a 2-month extension of the comment period. NDMA states that the request was on behalf of member companies who manufacture and distribute over-the-counter (OTC) acne drug products containing benzoyl peroxide. NDMA indicated that it intended to comment on FDA's proposal to require additional labeling on acne drug products at the request of its Benzoyl Peroxide Study Group. NDMA stated that it needed more time to document fully questions about certain facts included in the proposal. NDMA added that the precedent-breaking nature of the agency's proposal demanded careful scrutiny and thoughtful consideration and that coordination of the Benzoyl Peroxide Study Group's efforts in these regards was time-consuming.

FDA has carefully considered the request and acknowledges the uniqueness of the proposal. The agency believes that additional time for comment is in the public interest and will be of assistance in establishing labeling that will help consumers safely use drug products containing benzoyl peroxide for the treatment of acne. Accordingly, the comment period is extended to July 17, 1995.

Interested persons may, on or before July 17, 1995, submit to the Dockets Management Branch (address above) written comments regarding the proposal. Three copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

Dated: May 16, 1995.

William K. Hubbard,

Acting Deputy Commissioner for Policy.

[FR Doc. 95–12399 Filed 5–18–95; 8:45 am]

BILLING CODE 4160–01–F

21 CFR Part 896

[Docket No. 83N–0193]

RIN 0905–AD83

Performance Standard for the Infant Apnea Monitor; Extension of Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Proposed rule; extension of comment period.

SUMMARY: The Food and Drug Administration (FDA) is extending to August 21, 1995, the comment period on the proposed rule that published in the **Federal Register** of February 21, 1995 (60 FR 9762). The document proposed to establish a mandatory performance standard for infant apnea monitors, which are a subset of breathing frequency monitors, also called neonatal apnea monitors. The infant apnea monitor is a system intended for use on infants to detect cessation of breathing. This action is based on a request from industry.

DATES: Written comments by August 21, 1995.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: James J. McCue, Center for Devices and Radiological Health (HFZ–84), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301–594–4765.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of February 21, 1995 (60 FR 9762), FDA published a proposed rule to establish a mandatory performance standard for infant apnea monitors, which are a subset of breathing frequency monitors, also called neonatal apnea monitors. The infant apnea monitor is a system intended for use on infants to detect cessation of breathing. FDA believes that a performance standard is necessary to ensure that infant apnea monitors accurately and reliably detect the absence of effective respiration and provide an alarm in such cases.

Interested persons were invited to comment by May 22, 1995. FDA received one request from industry to extend the comment period for 90 days. The request stated that this timeframe would allow sufficient time to gather the necessary data to develop effective comments.

FDA is extending the comment period for 90 days to ensure adequate time for preparation of comments. Accordingly, FDA finds under section 520(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360j(d)) that there is good cause for such an extension.

Interested persons may, on or before August 21, 1995, submit to the Dockets Management Branch (address above) written comments regarding this notice. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

Dated: May 10, 1995.

Joseph A. Levitt,

Deputy Director for Regulations Policy, Center for Devices and Radiological Health.

[FR Doc. 95–12293 Filed 5–18–95; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF THE TREASURY

Internal Revenue Service

26 CFR Part 1

[PS–013–88]

RIN 1545–AL57

Certain Publicly Traded Partnerships Treated as Corporations; Correction

AGENCY: Internal Revenue Service, Treasury.

ACTION: Correction to notice of proposed rulemaking and notice of public hearing.

SUMMARY: This document contains corrections to the notice of proposed rulemaking and notice of public hearing (PS–013–88) which was published in the **Federal Register** on Tuesday, May 2, 1995 (60 FR 21475), relating to the classification of certain publicly traded partnerships as corporations.

FOR FURTHER INFORMATION CONTACT: Christopher T. Kelley, (202) 622–3080, (not a toll-free call).

SUPPLEMENTARY INFORMATION:

Background

The notice of proposed rulemaking and notice of public hearing that is the subject of these corrections proposes to add § 1.7704–1 to the Income Tax Regulations relating to the definition of a publicly traded partnership under section 7704(b) of the Internal Revenue Code.

Need for Correction

As published, the notice of proposed rulemaking and notice of public hearing